As of 2026-03-12, the EV/EBITDA ratio of Flexion Therapeutics Inc (FLXN) is -7.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FLXN's latest enterprise value is 568.34 mil USD. FLXN's TTM EBITDA according to its financial statements is -78.25 mil USD. Dividing these 2 quantities gives us the above FLXN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 16.8x | 15.4x |
| Forward P/E multiples | 16.9x - 22.3x | 19.0x |
| Fair Price | (79.77) - (79.42) | (81.14) |
| Upside | -415.2% - -413.8% | -420.6% |
| Date | EV/EBITDA |
| 2026-03-11 | -7.27 |
| 2026-03-10 | -7.29 |
| 2026-03-09 | -7.29 |
| 2026-03-06 | -7.25 |
| 2026-03-05 | -7.29 |
| 2026-03-04 | -7.32 |
| 2026-03-03 | -7.29 |
| 2026-03-02 | -7.32 |
| 2026-02-27 | -7.32 |
| 2026-02-26 | -7.36 |
| 2026-02-25 | -7.36 |
| 2026-02-24 | -7.35 |
| 2026-02-23 | -7.35 |
| 2026-02-20 | -7.36 |
| 2026-02-19 | -7.35 |
| 2026-02-18 | -7.35 |
| 2026-02-17 | -7.35 |
| 2026-02-13 | -7.35 |
| 2026-02-12 | -7.34 |
| 2026-02-11 | -7.35 |
| 2026-02-10 | -7.35 |
| 2026-02-09 | -7.35 |
| 2026-02-06 | -7.34 |
| 2026-02-05 | -7.32 |
| 2026-02-04 | -7.33 |
| 2026-02-03 | -7.33 |
| 2026-02-02 | -7.34 |
| 2026-01-30 | -7.33 |
| 2026-01-29 | -7.33 |
| 2026-01-28 | -7.33 |
| 2026-01-27 | -7.34 |
| 2026-01-26 | -7.34 |
| 2026-01-23 | -7.33 |
| 2026-01-22 | -7.34 |
| 2026-01-21 | -7.33 |
| 2026-01-20 | -7.31 |
| 2026-01-16 | -7.32 |
| 2026-01-15 | -7.32 |
| 2026-01-14 | -7.32 |
| 2026-01-13 | -7.32 |
| 2026-01-12 | -7.32 |
| 2026-01-09 | -7.31 |
| 2026-01-08 | -7.31 |
| 2026-01-07 | -7.31 |
| 2026-01-06 | -7.31 |
| 2026-01-05 | -7.30 |
| 2026-01-02 | -7.28 |
| 2025-12-31 | -7.28 |
| 2025-12-30 | -7.29 |
| 2025-12-29 | -7.28 |